Patents by Inventor Gernot Schabbauer

Gernot Schabbauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200061165
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Application
    Filed: November 11, 2019
    Publication date: February 27, 2020
    Inventors: Gernot Schabbauer, Stephan Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Patent number: 10532086
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: January 14, 2020
    Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITED
    Inventors: Gernot Schabbauer, Stephan Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Publication number: 20180085440
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Application
    Filed: December 6, 2017
    Publication date: March 29, 2018
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Patent number: 9867875
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 16, 2018
    Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITED
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Patent number: 9789169
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 17, 2017
    Assignee: Bio-Cancer Treatment International Limited
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Publication number: 20160367648
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Application
    Filed: May 18, 2016
    Publication date: December 22, 2016
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Publication number: 20150315561
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Application
    Filed: April 28, 2015
    Publication date: November 5, 2015
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin, Paul Cheng, Li Chen
  • Publication number: 20080313751
    Abstract: Here is described a novel gene, the interferon inducible gene 12 (ISG12, IFI27), that interacts with nuclear receptors and enhances nuclear export of such transcription factors. As a consequence, the transcriptional activities of these nuclear receptors are decreased. As examples effects on NR4A1 and PPARa and PPARg are given. When ISG12 is absent as in ISG12 deficient mice transcriptional activities of these nuclear receptors are not impaired and their protective effects are fully appreciated. Consistently, ISG12 deficient mice are resistant to restenosis upon carotid artery ligation and to endotoxin induced death. Human genetics studies indicate the importance of ISG12 where the inventors could show a strong association between an intronic ISG12 SNP and the presence of hypercholesterolemia, diabetes type 2 and stroke. ISG12 is therefore a target for novel therapeutic strategies for the treatment of vascular diseases.
    Type: Application
    Filed: October 31, 2006
    Publication date: December 18, 2008
    Inventors: Nikolina Papac-Milicevic, Pavel Uhrin, Gernot Schabbauer, Elisabeth Binder, Bernd Binder